The Biosimilars Council commends Senators Cornyn and Bennet for the introduction of the Increasing Access to Biosimilars Act. This bipartisan proposal is based on a simple idea – that Medicare policies should encourage the use of the most effective, lowest cost medicine. Biosimilars consistently deliver savings compared to high-priced brand biologics. We encourage Congress and the Administration to quickly implement this policy and deliver savings to America’s patients and taxpayers.
ATTRIBUTE TO: Christine Simmon, Executive Director
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
